References
- Chao Q, Sprankle KG, Grotzfeld RM, et al. (2009). Identification of N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor. J Med Chem 52:7808–16
- Cortes JE, Kantarjian H, Foran JM, et al. (2013a). Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. J Clin Oncol 31:3681–7
- Cortes JE, Perl AE, Dombret H, et al. (2013b). Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line chemotherapy or previous bone marrow transplant. J Clin Oncol 31: abstract 7012
- Gilliland DG, Griffin JD. (2002). Role of FLT3 in leukemia. Curr Opin Hematol 9:274–81
- Greenman C, Stephens P, Smith R, et al. (2007). Patterns of somatic mutation in human cancer genomes. Nature 446:153–8
- Hop CE, Wang Z, Chen Q, et al. (1998). Plasma-pooling methods to increase throughput for in vivo pharmacokinetic screening. J Pharm Sci 87:901–3
- Kiyoi H, Towatari M, Yokota S, et al. (1998). Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333–7
- Kiyoi H, Yanada M, Ozekia K. (2005). Clinical significance of FLT3 in leukemia. Int J Hematol 82:85–92
- Kottaridis PD, Gale RE, Frew ME, et al. (2001). The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752–9
- Lin TL, Levy MY. (2012). Acute myeloid leukemia: focus on novel therapeutic strategies. Clin Med Insights Oncol 6:205–17
- Lynch TJ, Bell DW, Sordella R, et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–39
- Nakao M, Yokota S, Iwai T, et al. (1996). Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911–18
- Paez JG, Jänne PA, Lee JC, et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–500
- Patel HK, Grotzfeld RM, Lai AG, et al. (2009). Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors. Bioorg Med Chem Lett 19:5182–5
- Rombouts W, Blokland I, Löwenberg B, et al. (2000). Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 14:675–83
- Sanga M, Banach J, Ledvina A, et al. (2016). Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers. Xenobiotica 21:1–16
- Sawyers CL. (2003). Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17:2998–3010
- Zarrinkar PP, Gunawardane RN, Cramer MD, et al. (2009). AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 114:2984–92
- Zhang D, Raghavan N, Chen SY, et al. (2008). Reductive isoxazole ring opening of the anticoagulant razaxaban is the major metabolic clearance pathway in rats and dogs. Drug Metab Dispos 36:303–15